- Home
- SAGE vs XERS Comparison
SAGE vs XERS Comparison
Compare SAGE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- XERS
- Stock Information
- Founded
- SAGE 2010
- XERS 2005
- Country
- SAGE United States
- XERS United States
- Employees
- SAGE N/A
- XERS N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- XERS Health Care
- Exchange
- SAGE Nasdaq
- XERS Nasdaq
- Market Cap
- SAGE 462.2M
- XERS 509.9M
- IPO Year
- SAGE 2014
- XERS 2018
- Fundamental
- Price
- SAGE $5.61
- XERS $3.49
- Analyst Decision
- SAGE Hold
- XERS Buy
- Analyst Count
- SAGE 19
- XERS 3
- Target Price
- SAGE $11.53
- XERS $4.87
- AVG Volume (30 Days)
- SAGE 1.1M
- XERS 1.7M
- Earning Date
- SAGE 02-12-2025
- XERS 11-08-2024
- Dividend Yield
- SAGE N/A
- XERS N/A
- EPS Growth
- SAGE N/A
- XERS N/A
- EPS
- SAGE N/A
- XERS N/A
- Revenue
- SAGE $106,399,000.00
- XERS $187,361,000.00
- Revenue This Year
- SAGE N/A
- XERS $23.48
- Revenue Next Year
- SAGE $122.78
- XERS $18.69
- P/E Ratio
- SAGE N/A
- XERS N/A
- Revenue Growth
- SAGE 837.60
- XERS 22.72
- 52 Week Low
- SAGE $4.62
- XERS $1.69
- 52 Week High
- SAGE $28.26
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- SAGE 50.27
- XERS 55.91
- Support Level
- SAGE $4.94
- XERS $3.17
- Resistance Level
- SAGE $5.91
- XERS $3.63
- Average True Range (ATR)
- SAGE 0.36
- XERS 0.19
- MACD
- SAGE 0.02
- XERS -0.02
- Stochastic Oscillator
- SAGE 69.07
- XERS 45.71
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.